DL
Insider
David Charles Lubner
DirectorDavid Charles Lubner (Director) filed 2 Form 4 reports in the trailing twelve months (1 purchase, 1 sale), most often in ACLX. Across 1 priced purchase filing, the average 21-session return was -10.0% from execution and -10.0% from disclosure (delay-adjusted; derived). The largest single filing was $1000K of BRVE (55,555 sh × $18.00, as filed), executed Aug 7.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-10.0%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-10.0%
same 1 filings, from disclosure
Filings, ttm
2
1 buys · 1 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$1.4M
shares × price, as filed
Last traded
Aug 7
Filed Aug 7
Volume by month
Buys $1000K
Sells $450K
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Not on file
1 filing
Sector per market data · by filing · past 12 months
Most traded names
ACLX
ACLX
ACLX · 0 buys · 1 sell
1 filing
BRVERecent filings
BRVEPURCHASE
Braveheart Bio, Inc.
View filing →
$1000K55,555 sh × $18.00
Exec Aug 7
Filed Aug 7 · 4:30 PM ET ACLXSALE Arcellx, Inc. View filing → $450K
6,000 sh × $75.00
Exec Jan 20
Filed Jan 20 · 5:30 PM ET